NASDAQ:VYNT

Vyant Bio - VYNT Stock Forecast, Price & News

$0.54

+0.00 (+0.44%)

(As of 09/27/2022 04:31 PM ET)

Add

Compare

Today's Range: $0.53
▼
$0.58
50-Day Range: $0.54
▼
$0.89
52-Week Range: $0.50
▼
$3.24

Volume: 9,309 shs
Average Volume: 216,408 shs
Market Capitalization: $15.92 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Vyant Bio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 426.1% Upside
$3.00 Price Target
Short Interest: Healthy
0.39% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.57) to ($0.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

665th out of 1,071 stocks

Medical Laboratories Industry

22nd out of 29 stocks

3.5

Analyst's Opinion

Consensus Rating
Vyant Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Vyant Bio has a forecasted upside of 426.1% from its current price of $0.57.
Amount of Analyst Coverage
Vyant Bio has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.39% of the float of Vyant Bio has been sold short.
Short Interest Ratio / Days to Cover
Vyant Bio has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vyant Bio has recently increased by 20.62%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Vyant Bio does not currently pay a dividend.
Dividend Growth
Vyant Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VYNT.

N/A

News and Social Media Coverage

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vyant Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.77% of the stock of Vyant Bio is held by insiders.
Percentage Held by Institutions
Only 5.52% of the stock of Vyant Bio is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Vyant Bio are expected to grow in the coming year, from ($0.57) to ($0.50) per share.
Price to Book Value per Share Ratio
Vyant Bio has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vyant Bio (NASDAQ:VYNT) Stock

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.

Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Stock News Headlines

September 13, 2022 | msn.com

Looking Into Vyant Bio's Return On Capital Employed

September 1, 2022 | finance.yahoo.com

Vyant Bio to Deliver a Live Presentation at the Skyline Signature Series™ on Thursday, September 8, 2022

August 31, 2022 | finance.yahoo.com

Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 23, 2022 | proactiveinvestors.com

NA Proactive news snapshot: Predictmedix, Lion Copper and Gold,...

August 23, 2022 | proactiveinvestors.com

Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year

August 22, 2022 | seekingalpha.com

Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call Transcript

August 22, 2022 | finance.yahoo.com

Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights

August 19, 2022 | finance.yahoo.com

Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022

August 16, 2022 | bizjournals.com

Vyant Bio cancels investor call over 'recent developments' with the potential sale of subsidiary

August 15, 2022 | finance.yahoo.com

Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast

August 11, 2022 | nasdaq.com

Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates

August 11, 2022 | finance.yahoo.com

Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022

August 9, 2022 | nasdaq.com

Immatics (IMTX) Reports Q2 Loss, Lags Revenue Estimates

August 3, 2022 | finance.yahoo.com

Vyant Bio to Present at Investor Summit Group's Q3 Virtual Conference

July 20, 2022 | benzinga.com

Vyant Bio (NASDAQ: VYNT) Engages Skyline Corporate Communications Group, LLC To Continue Advancing Its Communications With The Financial Industry

June 1, 2022 | finance.yahoo.com

Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services

May 19, 2022 | finance.yahoo.com

Vyant Bio to Present at the H.C. Wainwright Global Investment Hybrid Conference

May 16, 2022 | seekingalpha.com

Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q1 2022 Results - Earnings Call Transcript

May 16, 2022 | investing.com

Vyant Bio Reports Q1 Loss from Cont. Operations of $0.15

May 16, 2022 | nasdaq.com

Vyant Bio vs. Bitcoin: Price Relationship Crosses Threshold

May 16, 2022 | proactiveinvestors.com

Vyant Bio ends 1Q with $16.4M in cash to fund small molecule therapeutics research for neurological diseases

May 16, 2022 | finance.yahoo.com

Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights

May 10, 2022 | finance.yahoo.com

Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022

May 5, 2022 | finance.yahoo.com

Vyant Bio Announces Participation in BioNJ’s 12th Annual BioPartnering Conference

April 13, 2022 | proactiveinvestors.com.au

Vyant Bio enters collaboration with Organo Therapeutics to find treatments for Parkinson's Disease

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Company Calendar

Last Earnings: 11/11/2021
Today: 9/27/2022
Next Earnings (Estimated): 11/10/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VYNT
CUSIP: N/A
CIK: 1349929
Web: stemonix.com
Phone: (201) 479-1357
Fax: 201-528-9201
Employees: 40
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +453.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,860,000.00
Net Margins: N/A
Pretax Margin: -1,475.46%
Return on Equity: -50.63%
Return on Assets: -40.44%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 2.16
Quick Ratio: 2.11

Sales & Book Value

Annual Sales: $1.15 million
Price / Sales: 13.84
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.08 per share
Price / Book: 0.50

Miscellaneous

Outstanding Shares: 29,343,000
Free Float: 26,476,000
Market Cap: $15.92 million
Optionable: Not Optionable
Beta: 1.87

Key Executives

Mr. John A. Roberts M.B.A. (Age 63)
MBA, Pres, CEO & Director
Comp: $597.69k

Mr. Yung-Ping Yeh M.B.A. (Age 46)
M.S., P.M.P., Co-Founder & Director
Comp: $351.45k

Mr. Andrew D.C. LaFrence CPA (Age 59)
CPA, Chief Financial Officer
Comp: $355.34k

Dr. Robert Thomas Fremeau Jr. (Age 67)
Ph.D., Chief Scientific Officer

Dr. Robert J. Petcavich Ph.D. (Age 68)
Chief Science Advisor & Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VYNT Stock - Frequently Asked Questions

Should I buy or sell Vyant Bio stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VYNT shares.
View VYNT analyst ratings or view top-rated stocks.
What is Vyant Bio's stock price forecast for 2022?: 1 Wall Street analysts have issued 12-month target prices for Vyant Bio's shares. Their VYNT share price forecasts range from $3.00 to $3.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 426.1% from the stock's current price.
View analysts price targets for VYNT or view top-rated stocks among Wall Street analysts.
How have VYNT shares performed in 2022?: Vyant Bio's stock was trading at $1.35 at the start of the year. Since then, VYNT stock has decreased by 57.8% and is now trading at $0.5702.
View the best growth stocks for 2022 here.
When is Vyant Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our VYNT earnings forecast.

How were Vyant Bio's earnings last quarter?: Vyant Bio, Inc. (NASDAQ:VYNT) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($0.15) earnings per share for the quarter, meeting the consensus estimate of ($0.15). The business had revenue of $1.51 million for the quarter, compared to analysts' expectations of $2.19 million. During the same quarter last year, the business posted ($0.58) earnings per share.
What is Vyant Bio's stock symbol?: Vyant Bio trades on the NASDAQ under the ticker symbol "VYNT."
How do I buy shares of Vyant Bio?: Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vyant Bio's stock price today?: One share of VYNT stock can currently be purchased for approximately $0.57.
How much money does Vyant Bio make?: Vyant Bio (NASDAQ:VYNT) has a market capitalization of $16.73 million and generates $1.15 million in revenue each year.
How can I contact Vyant Bio?: Vyant Bio's mailing address is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. The official website for the company is stemonix.com. The company can be reached via phone at (201) 479-1357, via email at jzimmons@zimmonsic.com, or via fax at 201-528-9201.

This page (NASDAQ:VYNT) was last updated on 9/27/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial